|
|
Article: FDA Approves Risperdal for Two Psychiatric Conditions in Children and Adolescents.
- Article from:
- M2 Presswire
- Article date:
- August 23, 2007
CopyrightCOPYRIGHT 2007 M2 Communications Ltd. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
M2 PRESSWIRE-23 August 2007-US FDA: FDA Approves Risperdal for Two Psychiatric Conditions in Children and Adolescents(C)1994-2007 M2 COMMUNICATIONS LTD
RDATE:22082007
The U.S. Food and Drug Administration today approved Risperdal (risperidone) for the treatment of schizophrenia in adolescents, ages 13 to 17, and for the short-term treatment of manic or mixed episodes of bipolar I disorder in children and adolescents ages 10 to 17. This is the first FDA approval of an atypical antipsychotic drug to treat either disorder in these age groups.
Until now, there has been no FDA-approved drug for the treatment of schizophrenia for pediatric use and ...